)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Amniotics
Amniotics (AMNI) investor relations material
Amniotics has been delisted
Amniotics Q2 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2024 earnings summary20 Aug, 2024
Executive summary
Amniotics develops cell therapies based on neonatal mesenchymal stem cells from amniotic fluid, with a unique patented technology and in-house GMP manufacturing in Lund.
The company faced significant challenges raising capital, leading to a planned merger with Magle Chemoswed Holding AB, creating "Nya Magle Group".
PulmoStem™, the lead product, completed a clinical study in 2023 showing positive safety and tolerability data; other pipeline candidates remain in early development.
Financial highlights
Net sales for H1 2024 were SEK 2.45 million, up from SEK 0 in H1 2023.
Operating result before depreciation was SEK -10.6 million (improved from SEK -16.6 million year-over-year).
Total comprehensive income was SEK -7.7 million, an improvement from SEK -18.4 million in H1 2023.
Cash flow for the period was SEK -8.0 million; cash and cash equivalents at period end were SEK 0.2 million.
Equity at period end was SEK 8.1 million, with an equity ratio of 47%.
Outlook and guidance
The merger with Magle Chemoswed is expected to be completed by October 3, 2024, securing the future of Amniotics' assets and staff.
Short-term capital needs are covered through loan extensions and service agreements with Magle Chemoswed.
The company aims to advance PulmoStem™ to Phase II/partnership and continue developing its pipeline.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Amniotics
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Amniotics AB is a Swedish biotechnology company focused on developing stem cell-based therapeutics for severe, life-threatening diseases. The company specializes in mesenchymal stem cells (MSCs) derived from amniotic fluid, which are used to create targeted treatments for various conditions. Amniotics has developed several product candidates, including PulmoStem, aimed at treating lung diseases, CogniStem for central nervous system disorders, NephroStem for kidney conditions, and CutiStem for skin therapies. The company is headquartered in Lund, Sweden, and its shares are listed on the Stockholm Stock Exchange.